C
ABVX

Covestor’s Abivax ABVX Stock Holding History

Covestor’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
6,774
+5,883
+660% +$666K 0.52% 32
2026
Q1 		$99K Sell
891
-83
-9% -$9.82K 0.07% 293
2025
Q4 		$131K Sell
974
-162
-14% -$17.7K 0.07% 409
2025
Q3 		$96K Buy
+1,136
New +$69.6K 0.05% 592
2025
Q2 		– Sell
-2,660
Closed -$17K – 2137
2025
Q1 		$17K Buy
+2,660
New +$18K 0.01% 1241

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Covestor's ABVX Position: Q2 2026 in Review

Covestor increased its Abivax (ABVX) stake by 660% in Q2 2026, buying an estimated $666K and bringing the position to 6,774 shares worth $902K. The position accounts for 0.52% of the portfolio, ranked #32.

Covestor first reported a position in ABVX in Q1 2025 and has held it in 5 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Covestor held 6,774 shares of Abivax worth $902K as of Q2 2026.
  • Covestor bought 5,883 Abivax shares in Q2 2026, an estimated $666K.
  • Abivax made up 0.52% of Covestor's portfolio in Q2 2026, its #32 holding.
  • Covestor first reported a position in Abivax in Q1 2025 and has held it in 5 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.